All In Biotech

Drug Trial Radar · NCT01056419

The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy

Last checked: Nov 20, 2026Latest source record: Jan 26, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 2009

Primary completion

Jun 2010

Study completion Aug 2010

Sponsor

Lead sponsor
Ankara UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The relationship between the method of the treatment of hyperthyroidism due to Graves' disease and the course of Graves' ophthalmopathy is debated. The investigators aimed to compare the results of total thyroidectomy done in 6 months following the appearance of the symptoms of ophthalmopathy and the antithyroid drug therapy in patients with moderate to severe Graves' ophthalmopathy. The inclusion criteria: 1)Hyperthyroidism and moderate to severe Graves' ophthalmopathy within 6 months, 2)Thyroid volumes greater than or equal to 15 mL in thyroid ultrasonography, 3)Patients taking no treatment except local medications for Graves' ophthalmopathy, 4)Clinical activity score of 3/7 or more, proptosis greater than or equal to 21 mm in one eye or 2 mm difference between two eyes, presence of diplopia, the opening of the eye lid greater than or equal to 9 mm. All patients will be treated with antithyroid drug until TSH levels of the patients are between 0.4-1. During this period all the patients will take pulse methyl prednisolone treatment of a total dose of 4.5 gr. After pulse steroid treatment the patients will be randomised to two groups: one group will be sent to surgery for total thyroidectomy, and their TSH levels will be kept between 0.4-1 with levothyroxine treatment; the other group will be followed under antithyroid drug treatment and their TSH levels will be kept between 0.4-1 also. The smoking habits will be asked. Serum TSH, fT4 levels, Hertelmeter and eye lid opening measurements, clinical activity scores, diplopia will be evaluated monthly; TSH receptor antibody, anti-thyroid peroxidase and anti-thyroglobulin levels will be measured in 3 months intervals for a period of 12 months.

Conditions

  • Graves' Ophthalmopathy

Interventions

  • Total ThyroidectomyProcedure

    Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy

  • PropylthiouracilDrug

    150-600 mg in two-three divided doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in the proptosis and activity of Graves' ophthalmopathyTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department

    Ankara, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.